Editorials
High cost of new drugs
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4136 (Published 27 July 2016) Cite this as: BMJ 2016;354:i4136Related articles
- AnalysisBetting on hepatitis C: how financial speculation in drug development influences access to medicinesPublished: 27 July 2016; BMJ 354 doi:10.1136/bmj.i3718
- Feature Published: 27 July 2016; BMJ 354 doi:10.1136/bmj.i4117
- Letter Published: 23 August 2016; BMJ 354 doi:10.1136/bmj.i4524
- Letter Published: 05 October 2016; BMJ 355 doi:10.1136/bmj.i5314
- News Published: 10 October 2016; BMJ 355 doi:10.1136/bmj.i5493
- Analysis Published: 08 October 2020; BMJ 371 doi:10.1136/bmj.m3841
- Analysis Published: 27 June 2022; BMJ 377 doi:10.1136/bmj-2022-070876
See more
- Introductory AddressProv Med Surg J October 03, 1840, s1-1 (1) 1-4; DOI: https://doi.org/10.1136/bmj.s1-1.1.1
- Report of the Meeting of the Eastern Branch of the Provincial Association at Bury St. Edmond'sProv Med Surg J October 03, 1840, s1-1 (1) 10-13; DOI: https://doi.org/10.1136/bmj.s1-1.1.10
- Mr. Warburton's Bill for the Regulation of the Medical ProfessionProv Med Surg J October 03, 1840, s1-1 (1) 13-15; DOI: https://doi.org/10.1136/bmj.s1-1.1.13
- An Atlas of Plates, illustrative of the Principles and Practice of Obstetric Medicine and Surgery, with descriptive LetterpressProv Med Surg J October 03, 1840, s1-1 (1) 4; DOI: https://doi.org/10.1136/bmj.s1-1.1.4
- A Practical Treatise on the Diseases peculiar to Women, illustrated by Cases, &cProv Med Surg J October 03, 1840, s1-1 (1) 4-5; DOI: https://doi.org/10.1136/bmj.s1-1.1.4-a
Cited by...
- Healthcare systems must get fair value for their data
- Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
- Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas
- Questions hang over European patent for hepatitis C drug after ruling
- Compulsory licences for direct acting antiviral drugs for hepatitis C
- Regulatory agencies should engage in drug pricing
- Patents: problem or panacea?